Pharmaceutical pricing policies in Australia

Pharmaceutical Prices in the 21st Century

Volumn , Issue , 2015, Pages 1-23

  Vitry, Agnes Isabelle ^a   Thai, Loc ^a   Roughead, Elizabeth E ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943403176     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-12169-7_1     Document Type: Chapter

References (86)

1. Australian Productivity Commission (2001) International pharmaceutical price differences. http://www.pc.gov.au/projects/study/pbsprices/docs/finalreport. Accessed 19 Sept 2014
2. Australian Institute of Health and Welfare (2012) Australia's health 2012. AIHW. http://www. aihw.gov.au/publication-detail/?id=10737422172. Accessed 19 Sept 2014
3. Australian Institute of Health andWelfare (2013)Health expenditure Australia 2011-2012. http://www. aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129544656. Accessed 13 Sept 2014
4. Australian Government, Department of Health (2010) Memorandum of understanding between the Commonwealth of Australia and Medicines Australia. http://www.health.gov.au/internet/main/publishing.nsf/Content/further-PBS-reforms-Agreement. Accessed 14 June 2013
5. Australian Government, Department of Health (2012) Review of statin therapies. http://www.pbs. gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-07/review-of-statin-therapies. Accessed 15 Sept 2014
6. Australian Government, Department of Health (2014) Fees, patient contributions and safety net thresholds. History of PBS copayments and safety net thresholds. http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee. Accessed 24 April 2014
7. Australian Government, Department of Health (2014a) Aboriginal health services and the Pharmaceutical Benefits Scheme (PBS). http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-indigenous. Accessed 13 Sept 2014
8. Australian Government, Department of Health (2014b) Browse by brand premium. http://www. pbs.gov.au/browse/brand-premium. Accessed 15 Sept 2014
9. Australian Government, Department of Health (2014c) Life Saving Drugs Programme (LSDP). http://www.health.gov.au/lsdp. Accessed 13 Sept 2014
10. Australian Government, Department of Health (2014d) National Medicines Policy. http://www. health.gov.au/nationalmedicinespolicy. Accessed 15 Sept 2014
11. Australian Government, Department of Health (2014e) Pharmaceutical benefits for palliative care. http://www.pbs.gov.au/browse/palliative-care. Accessed 13 Sept 2014
12. Australian Government, Department of Health (2014f) Pharmaceutical Benefits Scheme (PBS) growth hormone programme. http://www.pbs.gov.au/info/browse/section-100/growth-hor mone-programme. Accessed 19 Sept 2014
13. Australian Government, Department of Health (2014g) Pharmacy location rules. Applicant's handbook. Version 1.1, March 2014. http://www.health.gov.au/internet/main/publishing.nsf/Content/DDB409EBB18FCE8FCA257BF0001D3C0C/$File/pharmacy-location-rules-hand book-v1.1-march-2014.pdf. Accessed 13 Sept 2014
14. Australian Government, Department of Health (2014h) Price disclosure (SPD). http://www.pbs. gov.au/info/industry/pricing/price-disclosure-spd. Accessed 14 Sept 2014
15. Australian Government, Department of Health (2014i) Quality use of medicines. http://www. health.gov.au/internet/main/publishing.nsf/Content/nmp-quality.htm-copy2. Accessed 15 Sept 2014
16. Australian Government, Department of Health (2014j) Report to parliament on the collection of PBS/RPBS under co-payment prescription data 2012-2013. http://www.health.gov.au/inter net/main/publishing.nsf/Content/14DEA08914F167C0CA257BF0001C96FC/$File/report-oncollection- pbs-under-co-payments-2012-13.pdf. Accessed 13 Sept 2013
17. Australian Government, Department of Health (2014k) Termination of the Pharmaceutical Benefits Pricing Authority (PBPA). http://www.pbs.gov.au/info/news/2014/03/termination-ofpbpa. Accessed 14 Sept 2014
18. Australian Government, Department of Health and Ageing (2005) Questions and answers on new pricing and listing arrangements for generic medicines on the Pharmaceutical Benefits Scheme (PBS). http://www.health.gov.au/internet/main/publishing.nsf/Content/8464B883F90180E1CA25732B0048D610/$File/qa_newpricing.pdf. Accessed 20 Sept 2011
19. Australian Government, Department of Health and Ageing (2010) The impact of PBS reform. http://www.pbs.gov.au/info/industry/useful-resources/impact-of-pbs-eform
20. Australian Government, Department of Health and Ageing (2011) Annual report 2010-2011. http://content.webarchive.nla.gov.au/gov/wayback/20140212092902/http://www.health.gov. au/internet/main/publishing.nsf/Content/FEB608DDB709DAC5CA257BF0001C6C8A/$File/DoHA%20Annual%20Report%202010-11.pdf. Accessed 15 Sept 2014
21. Australian Government, Department of Health and Ageing (2012a) Annual report 2011-2012. http://webarchive.nla.gov.au/gov/20140212095112/http://www.health.gov.au/internet/main/publishing.nsf/Content/Annual%20Reports-3. Accessed 14 Sept 2014
22. Australian Government, Department of Health and Ageing (2012b) Price reductions for main, first transitional and second transitional cycles. http://www.pbs.gov.au/info/industry/pricing/eapd/price-reductions. Accessed 24 Aug 2012
23. Australian Government, Department of Health and Ageing (2013a) Annual report 2012-2013. http://www.health.gov.au/internet/main/publishing.nsf/Content/annual-report2012-13. Accessed 18 Dec 2013
24. Australian Government, Department of Health and Ageing (2013b) Price reductions for second main cycle. http://www.pbs.gov.au/info/industry/pricing/eapd/price-reductions-for-secondmain- cycle. Accessed 15 June 2013
25. Australian Government, Department of Industry (2014) Regulation and pricing in the pharmaceuticals industry. http://www.industry.gov.au/industry/PharmaceuticalsandHealthTechnologies/Pharmaceuticals/Pages/RegulationandPricingInthePharmaceuticalsIndustry.aspx Accessed 13 Sept 2014
26. Australian Government, Department of Health (2014a) Drug Utilisation Sub Committee (DUSC). http://www.pbs.gov.au/info/industry/listing/participants/drug-utilisation-subcommittee. Accessed 15 Sept 2014
27. Australian Government, Department of Health (2014b) Post-market reviews of pharmaceutical benefits scheme subsidised medicines. http://www.pbs.gov.au/info/reviews/subsidised-medi cines-reviews. Accessed 15 Sept 2014
28. Australian Government, National Commission of Audit (2014) Towards responsible government. The report of the National Commission of Audit. http://www.ncoa.gov.au/report/docs/phase_ one_report.pdf. Accessed 13 Sept 2014
29. Australian Government, Department of Health, Therapeutic Goods Administration (2014a) About the TGA. Department of Health. http://www.tga.gov.au/about/index.htm#.U1nhLSTHHY8. Accessed 25 April
30. Australian Government, Department of Health, Therapeutics Goods Administration (2014b) Australian register of therapeutic goods. http://www.tga.gov.au/industry/artg.htm. Accessed 13 Sept 2014
31. Australian Government, Department of Human Services, Medicare (2014c) Late stage metastatic cancer. http://www.medicareaustralia.gov.au/provider/patients/late-breast-cancer.jsp#N10009. Accessed 19 Sept 2014
32. Australian Government, Department of Human Services, Medicare (2014d) Pricing of PBS medicine. http://www.medicareaustralia.gov.au/provider/pbs/pharmacists/pricing.jsp. Accessed 14 Sept 2014
33. Beecroft G (2007) Generic drug policy in Australia: a community pharmacy perspective. Australia and New Zealand Health Policy 4:7. doi:10.1186/1743-8462-4-7
34. Bulfone L (2009) High prices for generics in Australia: more competition might help. Australian Health Review 33(2):200-214
35. Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME (2012) International variability in the reimbursement of cancer drugs by publically funded drug programs. Current Oncology 19(3):e165-e176. doi:10.3747/co.19.946
36. Chim L, Kelly PJ, Salkeld G, Stockler MR (2010) Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics 28(6):463-475
37. Clarke PM (2012) Challenges and opportunities for the Pharmaceutical Benefits Scheme. Med J Aust 196(3):153-154
38. Clarke PM, Avery AB (2014) Evaluating the costs and benefits of using combination therapies. Med J Aust 200(9):518-520. doi:10.5694/mja14.00199
39. Clarke PM, Fitzgerald EM (2010) Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust 192(11):633-636
40. CoAG Reform Council (2014) Healthcare in Australia 2012-2013: Five years of performance. Report to the Council of Australian Governments. http://www.coagreformcouncil.gov.au/sites/default/files/files/Healthcare%20in%20Australia%202012-13%20Five%20years%20of% 20performance%20REVISED%20WA%20SNAPSHOT.pdf. Accessed 15 Sept 2014
41. Committee for Economic Development of Australia (2013) Healthcare: Reform or ration. https://www.ceda.com.au/media/302619/healthcarefinal1.pdf. Accessed 19 Sept 2014
42. Commonwealth of Australia, Pharmacy Guild of Australia (2010) The fifth community pharmacy agreement between the Commonwealth of Australia and the Pharmacy Guild of Australia https://www.health.gov.au/internet/main/publishing.nsf/Content/8D21C5E188499A03CA257 BF0001C963A/$File/5CPA%20Agreement%2005%20August%202010.pdf. Accessed 13 Sept 2014
43. Consumers Health Forum of Australia (2014a) Medicines savings-a good start… much more to do. http://ourhealth.org.au/medicines-savings-a-good-start-much-more-do. Accessed 15 Sept 2014
44. Consumers Health Forum of Australia (2014b) Submission to the National Commission of Audit. http://www.ncoa.gov.au/docs/submission-consumers-health-forum-of-australia.pdf. Accessed 15 Sept 2014
45. Council of Australian Governments (2012) National Health Care Agreement 2012. http://www. federalfinancialrelations.gov.au/content/npa/healthcare/national-agreement.pdf. Accessed 25 April 2014
46. Department of Health and Ageing, Medicines Australia (2013) Joint monitoring report on trends in and drivers of Pharmaceuticals Benefits Scheme expenditure. http://www.pbs.gov.au/publica tion/reports/trends-in-and-drivers-of-pbs-expenditure.docx. Accessed 14 Sept 2014
47. Duckett SJ, Breadon P, Ginnivan L, Venkataraman P (2013) Australia's bad drug deal: high pharmaceutical prices. Grattan Institute, Melbourne
48. Fenna A (2012) Centralising dynamics in Australian federalism. Australian Journal of Politics & History 58(4):580-590. doi:10.1111/j.1467-8497.2012.01654.x
49. Feros P (2011) Price deflation: outbreaks and antidotes. The Australian Journal of Pharmacy 92 (1093):60-63
50. Generic Medicines Industry Association (2014) The devastating impact of cost cutting on the generic medicines industry. http://www.gmia.com.au/wp-content/uploads/2014/03/GMiAFact- Sheet-3-Devastating-Impact-of-Accelerated-Price-Disclosure-Feb14.pdf. Accessed 15 Sept 2014
51. Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Bishop I, Bucsics A, Campbell S, Finlayson A (2014) Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Frontiers in Pharmacology 5:106
52. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J (2008) The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 17(11):1091-1099. doi:10.1002/pds.1670
53. PBS Information Management Section, Pharmaceutical Policy Branch (2013) Expenditure and prescriptions twelve months to 30 June 2013. Department of Health. http://www.pbs.gov.au/statistics/2012-2013-files/expenditure-and-prescriptions-12-months-to-30-06-2013.pdf. Accessed 24 April 2014
54. Karikios DJ, Schofield D, Salkeld G, Mann KP, Trotman J, Stockler MR (2014) Rising cost of anticancer drugs in Australia. Intern Med J 44(5):458-463. doi:10.1111/imj.12399
55. Lam M (2014) Half of out-of-pockets due to scripts. Pharma in focus. http://www.pharmainfocus. com.au/. Accessed 19 Sept 2014
56. Lofgren H (2009) Generic medicines in Australia: business dynamics and recent policy reform. Southern Med Review 2(2):24-28
57. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A (2010) Impact of restricted reimbursement on the use of statins in Finland. A register-based study. Med Care 48(9):761-766. doi:10.1097/MLR.0b013e3181e41bcb
58. Mauskopf J, Chirila C, Masaquel C, Boye KS, Bowman L, Birt J, Grainger D (2013) Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care 29(1):92-100. doi:10.1017/s0266462312000724
59. Medicines Australia (2010) The Australian pharmaceuticals industry. Winds of change http://medicinesaustralia.com.au/files/2011/03/20100603-pub-MedicinesAustralia-winds-of-Change. pdf. Accessed 13 Sept 2014
60. Medicines Australia (2014) 'Let them eat cake' the wrong PBS recipe. http://medicinesaustralia. com.au/media-events/from-the-chief-executive/. Accessed 19 Sept 2014
61. National Health Performance Authority (2013) Healthy Communities: Australians' experiences with access to health care in 2011-2012. http://www.nhpa.gov.au/internet/nhpa/publishing.nsf/Content/Our-reports. Accessed 15 Sept 2014
62. Ohlsson H, Vervloet M, van Dijk L (2011) Practice variation in a longitudinal perspective: a multilevel analysis of the prescription of simvastatin in general practices between 2003 and 2009. Eur J Clin Pharmacol 67(12):1205-1211. doi:10.1007/s00228-011-1082-8
63. Organisation for Economic Co-operation and Development (OECD) (2013) OECD Factbook 2013: Economic, Environmental and Social Statistics. Life expectancy. http://www.oecd-ilibrary.org/sites/factbook-2013-en/12/01/01/index.html;jsessionid=18hxihifu0815.x-oecd-live-01?itemId=/content/chapter/factbook-2013-95-en&_csp_=2e12af00b8816149004be44b35212040. Accessed 13 Sept 2014
64. Pettersson B, Hoffmann M, Wandell P, Levin LA (2012) Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104(1):84-91. doi:10.1016/j.healthpol.2011.10.010
65. Pharmaceutical Benefits Advisory Committee (2009) PBAC Review of bDMARDs for the treatment of severe active rheumatoid arthritis. http://www.health.gov.au/internet/main/publishing. nsf/Content/pbac-psd-bdmards-dec09. Accessed 14 June 2013
66. Pharmaceutical Benefit Advisory Committee (2013a) PBAC recommendations from the review of pharmaceutical benefits scheme anti-dementia drugs to treat Alzheimer disease. http://www. pbs.gov.au/info/reviews/pbac-minutes-alzheimers. Accessed 14 June 2013
67. Pharmaceutical Benefits Advisory Committee (2013b) November 2012 PBAC outcomes-Positive recommendations. http://www.health.gov.au/internet/main/publishing.nsf/content/healthpbs- general-listing-committee3.htm. Accessed 14 June 2013
68. Pharmaceutical Benefits Pricing Authority (2013) Appendix 2: pharmaceutical benefits pricing authority annual report for the year ended 30 June 2013. http://www.health.gov.au/internet/main/publishing.nsf/Content/53FCED10EAD1C98CCA257C0500786C41/$File/Appendix% 202%20Pharmaceutical%20Benefits%20Pricing%20Authority%20Annual%20Report.pdf. Accessed 14 Sept 2014
69. Pharmacy Guild of Australia (2014a) About 5CPA. http://5cpa.com.au/about-5cpa/. Accessed 13 Sept 2014
70. Pharmacy Guild of Australia (2014b) Pharmacy innovations in e-health. http://www.guild.org.au/docs/default-source/public-documents/issues-and-resources/Fact-Sheets/pharmacy-innovationsin- ehealth.pdf?sfvrsn=0. Accessed 14 Sept 2014
71. Pharmacy Guild of Australia (2014c) Submission to Senate Standing Committees on Community Affairs Inquiry: out-of-pockets costs in Australian healthcare http://www.aph.gov.au/Parliamen tary_Business/Committees/Senate/Community_Affairs/Australian_healthcare/Submissions. Accessed 15 Sept 2014
72. Plibersek T (2013) Transcript: doorstop on the price of medicines/antimicrobial resistance-Senate Courtyard, Parliament House, Canberra. http://pandora.nla.gov.au/pan/131355/20130702-1129/www.health.gov.au/internet/ministers/publishing.nsf/Content/tr-yr13-tp-tpsp130318b86c.htm? OpenDocument&yr=2013&mth=03. Accessed 19 Sept 2014
73. Puig-Junoy J (2010) Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics 28(8):649-663. doi:10.2165/11535360-000000000- 00000
74. Quilty D (2014) Pharmaceuticals, pharmacists and profits: the Pharmacy Guild perspective. Australian Prescriber 2014
75. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S (2007) Switching statins in Norway after new reimbursement policy-a nationwide prescription study. Br J Clin Pharmacol 64 (4):476-481. doi:10.1111/j.1365-2125.2007.02907.x
76. Senate Community Affairs References Committee (2014) Out-of-pocket costs in Australian healthcare. http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_ Affairs/Australian_healthcare/Report. Accessed 13 Sept 2014
77. Simoens S (2007) International comparison of generic medicine prices. Curr Med Res Opin 23 (11):2647-2654. doi:10.1185/030079907X233395
78. Simoens S, De Coster S (2006) Sustaining generic medicines markets in Europe. Katholieke Universiteit Leuven, Leuven
79. Spinks JM, Richardson JR (2011) Paying the right price for pharmaceuticals: a case study of why the comparator matters. Aust Health Rev 35(3):267-272, doi: AH10930 [pii] 10.1071/AH10930
80. Sweeny K (2013) The impact of further PBS reforms: report to medicines Australia. Victoria University, Melbourne
81. Thai LP, Vitry AI, Moss JR (2014) Discounting of medicines in Australian community pharmacies. Aust Health Rev. doi:10.1071/AH14012
82. The Commonwealth of Australia (2011) Framework for the introduction of parallel TGA and PBAC processes. http://www.pbs.gov.au/info/publication/factsheets/shared/framework-forintroduction- of-parallel-TGA-and-PBAC-processes. Accessed 28 June 2014
83. The Hon Peter Dutton MP, Minister for Health, Minister for Sport (2013) Media release. Australians to access more affordable medicines sooner. http://www.health.gov.au/internet/ministers/publishing.nsf/Content/4084C89B3E2171EBCA257C140001CA8C/$File/PD007. pdf. Accessed 18 Dec 2013
84. Vitry A, Roughead E (2014) Managed entry agreements for pharmaceuticals in Australia. Health Policy 117:345-352. doi:10.1016/j.healthpol.2014.05.005
85. Willis E, Reynolds L, Keleher H (eds) (2012) Understanding the Australian health care system. Elsevier, Sydney
86. World Health Organization (2014) Global Health Observatory (GHO). http://www.who.int/gho/en/. Accessed 19 Sept 2014